Targeted therapy outcomes in acrodermatitis continua of Hallopeau
Author Information
Author(s): Zhou ChaoJing, Hou YiYun, Wang YuFei, Lu JiLiang, Gao YaMei, Yin ZhiQiang
Primary Institution: Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University
Conclusion
Targeted therapies are effective for managing refractory acrodermatitis continua of Hallopeau, especially when traditional treatments fail.
Supporting Evidence
- IL-12/23 inhibitors showed a complete resolution rate of 52.6% within 22.4 weeks.
- TNF-α inhibitors had a complete resolution rate of 44.1% within 14.6 weeks.
- IL-17 inhibitors achieved a complete resolution rate of 26.1% within 24.0 weeks.
- Treatment responses were generally more evident in female patients than in male patients.
- Many patients faced risks of disability due to the condition.
Takeaway
This study looked at how well different treatments work for a rare skin condition called acrodermatitis continua of Hallopeau, finding that some new medicines help a lot.
Methodology
The study reviewed published data from MEDLINE and Embase, analyzing treatment outcomes from 66 records involving 134 patients.
Potential Biases
There may be reporting bias due to unreported treatment failures.
Limitations
The study lacks evidence from randomized controlled trials and strict monotherapies, and treatment failures are often not reported.
Participant Demographics
Mean age of participants was 44.0 years, with 45.5% being male.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website